Advanced searches left 3/3

Lymphopenia - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 26 September 2022

* If you want to update the article please login/register

COVID-19-associated Lymphopenia Pathogenesis Study in Blood

Coronavirus disease 2019 is an acute respiratory disease triggered by coronavirus severe acute respiratory syndrome coronavirus-2. The presence of elevated inflammatory biomarkers, coagulopathy, and lymphopenia are all typical of chronic disease. In COVID-19, Lymphopenia is a robust and consistent predictor of mortality. Patients with mild to moderate COVID-19, as well as those who have recently recovered from the disease will be recruited. Participants will be blood drawn via venipuncture or readily available venous access, as well as optional nasal and/or rectal swabs, as well as optional leukapheresy and echocardiogram for recovering patients. Leftover clinical specimens may also be used for analysis. Clinical and laboratory data from routine care will also be collected, as well as up to two follow-up visits may be needed for clinical purposes. Participants may re-enroll in the study after recovering from infection as recovered participants or when they experience a new outbreak.

Source link: https://clinicaltrials.gov/ct2/show/NCT04401436


A Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Idiopathic CD4 lymphopenia is characterized by persistent low CD4 counts, often in conjunction with CD8, natural killer, or B cell lymphopenia. In several of the ICL patients evaluated, new results from our group revealed a high prevalence of antilymphocyte antibodies. The U. S. Food and Drug Administration has provided recommendations for patients with systemic lupus erythematosus with autoantibodies and demonstrated effectiveness in both reducing symptoms and leading to a modest decline in autoantibodies. Patients with laboratory confirmation of antilymphocyte antibodies will be recruited in this open-label prospective single-arm study. The study drug's administration will follow the SLE protocol of 10 mg/kg at study entry, 2 weeks, 4 weeks, and monthly thereafter unless otherwise specified. This research will determine the effectiveness of belimumab in ICL, as well as aid in better knowing the role of autoantibodies in ICL pathogenesis.

Source link: https://clinicaltrials.gov/ct2/show/NCT04097561

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions